Tick Insights

Search Icon

Menu Toggle Icon

Skip to content
  • Home
  • Forex
  • CFD Indices
  • CFD Equities
  • Education
  • Events
Tick Insights

Tag: Sinopharm

CFD Trading – Buy Sinopharm (1099.HKE) at $18.50. Stop at $17.60 and Target at $19.90.

May 18, 2022May 18, 2022Shueh Ting Wong

SINOPHARM   Stock Code 1099.HKE

Outlook

Price managed to break and close above the cloud after being supported by the Conversion line support, changing the chart outlook from bearish to bullish.… Read More

Uncategorized CFD HK Trading Note, Sinopharm Leave a comment

CFD Trading – Buy Sinopharm (1099.HKE) at $21.50. Stop at $20.70 and Target at $23.10

October 19, 2021Shueh Ting Wong

SINOPHARM   Stock Code 1099.HKE

Outlook

Price broke and closed above the cloud during the last trading session, turning the stock outlook from bearish to bullish.… Read More

CFD Equities CFD HK Trading Note, Sinopharm Leave a comment

CFD Trading – Buy Sinopharm (1099.HKE) at $19.70. Stop at $18.60 and Target at $21.80.

April 6, 2021Shueh Ting Wong

SINOPHARM   Stock Code 1099.HKE

Outlook
Price broke and closed above the cloud during the last trading session, turning the stock outlook from bearish to bullish.… Read More

CFD Equities CFD HK Trading Note, Sinopharm Leave a comment

About Us

Tick Insights

UTRADE

Upcoming Webinar

US & HK ETF Available For CFD Trade

Stay Connected

Subscribe to this blog and receive notifications of new posts by email.

Like our Facebook page for the latest updates!

 SG UTRADE

Recent Posts

  • FX Commentary – U.S. Dollar Was Flat Despite A Weak US PPI Data
  • CFD Indices – Wall Streets Retreated As U.S. Treasury Yields Increased
  • FX Commentary – U.S. Dollar Fell On Tame Inflation Data
  • CFD Trading – Buy China Telecom (0728.HKE) at $2.80. Stop at $2.70 and Target at $3.00
  • CFD Trading – Sell HKEX (0388.HKE) at $342.20. Stop at $354.65 and Target at $317.40

Archives

Disclaimer

This information is prepared by personnel in UOB Kay Hian’s Alternative Products Department and is not the product of UOB Kay Hian’s Research Department. It is not a research report and is not intended as such, although a UOB Kay Hian Research report may be referenced as a link or as an attachment hereto.

Opinions expressed herein may differ from the opinions expressed by other areas of UOB Kay Hian, including research. This commentary is provided for information only. Neither the information nor any views expressed constitutes a solicitation for the purchase or sale of any securities or other financial instruments. It is not a personal recommendation, offer or solicitation to buy or sell.

Scroll to Top
 

Loading Comments...